Sugammadex

Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible

... Publication of Comparative Study Shows sugammadex Provides Significantly Faster Reversal of Profound...sthesiology (Vol. 109, No. 5)(1) demonstrated that sugammadex produced a significantly more rapid recovery from ...the median time to recovery was 2.7 minutes in the sugammadex group versus 49.0 minutes in the neostigmine group...

Sugammadex in Medical Technology

U.S. FDA Issues Action Letter for Sugammadex

KENILWORTH, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has issued a "not-approvable" letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia. ...

European Union's CHMP Issues Positive Opinion on Sugammadex

Anesthesiologists to have new tool that works within minutes, upon European approval KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

OSS, the Netherlands, June 11, 2007-Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmi...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as comp...

Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)

...s recommended to monitor the recovery of neuromuscular blockade. The use of sugammadex in patients with severe renal impairment is not recommended. In clinical ...duals, allergic-like reactions (i.e. flushing, erythematous rash) following sugammadex were reported. For full Prescribing Information please go to http://www....

BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union

...(moderate block) patients were administered either sugammadex or neostigmine plus glycopyrrolate. In the AURORA ... a TOF ratio of 0.9 occurred in 1.4 minutes in the sugammadex group compared to 17.6 minutes in the neostigmine/... were randomized to receive either rocuronium plus sugammadex or the rapid-onset, short- duration muscle relaxan...

FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent

...decision on approval is made. Upon FDA approval, sugammadex will be the first and only selective relaxant bind...duced by rocuronium and vecuronium within minutes. sugammadex allows for flexible dosing of muscle relaxation ag...e used. We will continue to work with FDA to bring sugammadex to the U.S. market as soon as possible so that ane...

Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia

... SAN FRANCISCO, Oct. 16 /PRNewswire/ -- sugammadex -- the novel selective relaxant binding agent (SRB...e Signal trial compared the efficacy and safety of sugammadex and neostigmine/glycopyrrolate for the reversal of...Spectrum trial compared the efficacy and safety of sugammadex for reversal of profound rocuronium-induced neurom...

Sugammadex in Biological Technology

Schering-Plough Announces Sugammadex New Drug Application Filed in Japan

KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) announced that Nippon Organon K.K., now part of Schering-Plough, has filed a New Drug Application with the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking marketing approval for its nov...

Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA

KENILWORTH, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the company's New Drug Application (NDA) for sugammadex. Sugammadex is specifically designed to...

Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year

...the U.S. Food and Drug Administration (FDA); and -- Filing regulatory submissions for important new agents and indications, which now include sugammadex and asenapine from Organon. "Schering-Plough now has four full years of accomplishments since we began this transformation," said Hassan. "In that t...

Schering-Plough Completes Acquisition of Organon BioSciences

...anon), an oral contraceptive; * ORG 50081 (from Organon), for the treatment of insomnia and potentially for hot flashes in menopausal women; * sugammadex (from Organon), for the reversal of neuromuscular blockade used as part of general anesthesia during surgical procedures; * Tablet-based subling...